It is possible that with the expansion of GLP-1 medications—glucagon-like peptide-1 receptor agonists, a class of drugs used to treat type 2 diabetes and, in some cases, moderate-to-severe obesity—we might see a notable change in BMI at the population level with time [68,69]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.